Partially verified 2026-05-09. Jang 2010 (PMC2823863) and Reichardt 2006 (PMC1664664) verified against local PDFs. Webster 2006 and Minichiello 2009 are closed-access (not_oa) — claims derived from those sources are unverified against full text and carry no-fulltext-access tags. See verified-scope in frontmatter.

TrkB receptor pathway (BDNF-NTRK2 signaling)

The TrkB pathway (BDNF → NTRK2/TrkB → MAPK/PI3K/PLC-γ → CREB) is the dominant neurotrophin-signaling axis for aging-relevant brain biology. It mediates synaptic plasticity, adult hippocampal neurogenesis, cognitive resilience, and neuronal survival. Activation depends on BDNF or NT-4/5 binding to the full-length TrkB receptor (TrkB.FL), triggering autophosphorylation and recruitment of three parallel effector arms. A key aging vulnerability is the isoform shift from signaling-competent TrkB.FL toward the dominant-negative truncated isoform TrkB.T1, which blunts BDNF responsiveness in the aged brain. This page covers the TrkB sub-pathway specifically; for pan-neurotrophin biology (TrkA/B/C + p75NTR + NGF/NT-3/NT-4/5), see neurotrophin-signaling.

Naming note: [[trkb-pathway]] is the canonical wikilink for this page. The NTRK2 kinase as an individual protein page (when seeded) will live at molecules/proteins/ntrk2.md to avoid ambiguity, as established by the pathway/protein naming convention in CLAUDE.md.

Receptor isoforms: TrkB.FL vs TrkB.T1

NTRK2 pre-mRNA is alternatively spliced to produce two major protein isoforms with opposing functional roles:

Feature	TrkB.FL (full-length)	TrkB.T1 (truncated)
Kinase domain	Present (catalytically active)	Absent
Autophosphorylation	Y515, Y705, Y706, Y816 (rat numbering; human UniProt Q16620: Y516, Y702/Y706/Y707, Y817)	None
Downstream signaling	Ras-MAPK, PI3K-Akt, PLC-γ	None (scaffold/dominant-negative)
BDNF binding	Yes	Yes
Primary function	Signaling transduction	Inhibits productive dimerization with TrkB.FL (dominant-negative); can also modulate BDNF availability via competitive binding ¹
Aging change	Decreases relative to T1	Increases relative to FL
Predominant cell type	Neurons (postsynaptic)	Astrocytes; neurons (variable)

The ratio TrkB.FL:TrkB.T1 declines with age in human hippocampus and temporal cortex ². In aged brain, T1 dominance effectively attenuates BDNF responsiveness even when BDNF ligand is present — a form of signaling-competence loss without ligand deficit. needs-replication — the Webster 2006 finding is from postmortem human tissue; prospective or longitudinal quantification of the FL:T1 ratio in living aging humans is lacking.

Activation mechanism

BDNF and NT-4/5 bind TrkB.FL extracellular domains, inducing receptor dimerization and transautophosphorylation at four key tyrosines ¹:

Y515 (Shc-binding site; juxtamembrane; human Q16620: Y516) → recruits Shc → Grb2 → Sos → Ras activation → MAPK-ERK arm
Y705/Y706 (activation loop; human Q16620: Y706/Y707) → kinase activation; required for all downstream signaling. Note: UniProt P15209 annotates a third activation-loop phosphotyrosine at rat Y701 (human Y702); functional distinction from Y705/Y706 pair not addressed in Reichardt 2006.
Y816 (PLC-γ1-binding site; C-terminal tail; human Q16620: Y817) → recruits PLC-γ1 → DAG + IP3 arm

Throughout this page, Y-site numbers follow rat NTRK2 (UniProt P15209) convention, which is standard in the experimental TrkB/LTP literature (Minichiello 2009; Jang 2010). Human NTRK2 (UniProt Q16620) positions are 1 higher at each site due to a signal peptide length difference.

FRS2 (FGF receptor substrate 2) also binds Y515-phosphorylated TrkB.FL to contribute to PI3K recruitment. The phosphotyrosine sites are shared architecture across all Trk receptors (TrkA/B/C); specificity is conferred by ligand (BDNF/NT-4 → TrkB vs NGF → TrkA) and by downstream adapter competition.

Three effector arms

Arm 1: Ras-MAPK-ERK1/2 → CREB → gene expression

Shc (via Y515) → Grb2-Sos complex → Ras-GTP → Raf-MEK1/2 → ERK1/2 phosphorylation → nuclear translocation → CREB (Ser133 phosphorylation by RSK2/MSK1) → CRE-element transcription ³.

Key transcriptional outputs:

Bdnf autoregulation (exon-IV-driven transcription) — positive feedback loop
Arc/Arg3.1 — immediate-early gene, required for LTP consolidation
Fos, Zif268 — activity-dependent plasticity genes
Pro-survival genes (Bcl-2)

This arm is required for long-term potentiation (LTP) induction and associative memory formation. Genetic disruption of TrkB.FL Y515 (Y515F knock-in mice) impairs hippocampus-dependent contextual fear conditioning ³.

Arm 2: PI3K-AKT-mTOR → protein synthesis, anti-apoptosis, dendritic remodeling

FRS2/Gab1 (via Y515/Y705) → PI3K catalytic subunit (p110) → PIP3 → PDK1 → AKT (Ser473/Thr308 phosphorylation) → multiple outputs:

mTORC1 activation (via TSC1/TSC2 inhibition) → ribosome biogenesis, dendritic protein synthesis → structural LTP
BAD phosphorylation (Ser136) → dissociation from BCL-2 → neuronal survival
FOXO3a nuclear exclusion → reduced pro-apoptotic gene expression
GSK3β inhibition → microtubule dynamics, dendritic spine remodeling

This arm connects to pi3k-akt-pathway and mtor — see those pages for canonical mechanistic detail. In the aging context, reduced TrkB-driven AKT activation is proposed to contribute to decreased anti-apoptotic tone in aged hippocampal neurons and reduced capacity for structural synaptic plasticity. needs-human-replication

Arm 3: PLC-γ-DAG-PKC / IP3-Ca²⁺ → CaMKII → LTP induction

PLC-γ1 (via Y816) → cleaves PIP2 into:

DAG → PKC activation → CaMKII → AMPAR trafficking to synapse → LTP expression
IP3 → ER Ca²⁺ release → Ca²⁺/CaM-CaMKII activation → AMPAR phosphorylation (GluA1 Ser831) → LTP

Disrupting TrkB.FL Y816 (Y816F knock-in) blunts hippocampal LTP and spatial memory without abolishing neuronal survival, demonstrating selective dependence on Arm 3 for synaptic modification independent of Arm 2 ³. needs-replication — Y816F result is from mice; human relevance not directly established.

The three-arm summary:

Arm	Proximal adapter	Key effector	Aging-relevant output
Ras-MAPK-ERK	Shc/Grb2	CREB	Gene expression for plasticity, Bdnf autoregulation
PI3K-AKT-mTOR	FRS2/Gab1	AKT, mTOR	Neuronal survival, dendritic protein synthesis
PLC-γ-IP3/DAG	PLC-γ1	CaMKII, PKC	LTP expression, AMPAR trafficking

Role in aging

Hippocampal decline and memory

BDNF-TrkB signaling supports adult hippocampal neurogenesis (subgranular zone, dentate gyrus). Neurogenesis declines with aging; reduced TrkB.FL activation is one proposed mechanism ¹. Correlative: hippocampal BDNF and TrkB.FL mRNA decrease across the human lifespan in temporal cortex (neonatal peak → age-related decline in TK+ isoform), while TrkB TK- (T1) remains more stable ². This isoform rebalancing toward T1 limits the effective signaling output per unit of BDNF ligand.

Cognitive aging: Aged rodents with impaired spatial memory show reduced phospho-TrkB (pY705) in hippocampus, and pharmacological TrkB activation (7,8-DHF) rescues spatial memory and synaptic plasticity in cognitively impaired aged rats ⁴. needs-human-replication — rodent-to-human extrapolation is plausible but not directly tested.

Alzheimer’s disease

Postmortem cortex from AD patients shows reduced TrkB.FL protein relative to age-matched controls. Reduced TrkB activation is proposed to contribute to deficient CREB-driven neuroprotective gene expression in AD neurons. Whether this is causal or secondary to neurodegeneration is not established. contradictory-evidence — some studies report BDNF reduction as primary; others argue TrkB downstream signaling failure is the key node.

Downstream processes

synaptic-plasticity — CREB-driven gene expression (Arm 1) + AMPAR trafficking (Arm 3) together constitute the molecular basis of LTP; TrkB is required for late-phase LTP (L-LTP) consolidation.
ltp-induction — Arm 3 (PLC-γ-CaMKII) directly gates AMPAR insertion at potentiated synapses.
hippocampal-neurogenesis — TrkB signaling on progenitor cells promotes survival and differentiation of newborn dentate granule neurons.

Pharmacology (aging-context)

Agent	Class	Target	Status	Notes
7,8-dihydroxyflavone (7,8-DHF)	Small-molecule TrkB agonist	TrkB.FL	Preclinical	BBB-penetrant; oral; activates TrkB via extracellular domain (CC-2 domain), not kinase; Kd ≈ 320 nM ⁵; rescues memory in aged rodents ⁴
LM22A-4	Small-molecule TrkB partial agonist	TrkB.FL (loop 2 domain)	Preclinical	Lower potency than 7,8-DHF; neuroprotective in TBI mouse models ⁶
ACD855/ACD856	Positive allosteric modulator (PAM)	TrkA + TrkB	Preclinical	Increased hippocampal ACh ~40%, restored age-induced cognitive deficit in 18-month mice in one study ⁷; needs-replication

Druggability-tier: 2. No FDA-approved TrkB agonist exists for any aging-related indication. 7,8-DHF and LM22A-4 are high-quality preclinical probes; their aging-context clinical stage is preclinical. Full drug-level data lives on the individual compound pages.

Cross-references:

semax — claims BDNF→TrkB axis activation per Russian primary literature; mechanism partially overlapping
dihexa — does NOT primarily signal via TrkB; earlier reports of c-Met-linked mechanism are in the literature; verify current consensus on dihexa page before drawing mechanistic parallels to TrkB

Relationship to parent pathway

neurotrophin-signaling covers the full four-neurotrophin, three-Trk + p75NTR landscape. The TrkB pathway is the largest single sub-pathway by aging-literature volume, warranting its own atomic page. Key distinctions from TrkA (NGF) and TrkC (NT-3): TrkB is the only Trk receptor prominently expressed by pyramidal neurons in hippocampus and cortex; TrkA is primarily expressed by cholinergic basal forebrain neurons (relevant to AD via septal-hippocampal projection); TrkC is enriched in proprioceptors and cerebellum. For the shared upstream signaling architecture (shared adapter binding, shared Ras-MAPK/PI3K/PLC-γ arms), see neurotrophin-signaling.

Limitations and gaps

TrkB.FL:T1 isoform ratio in aging — Webster 2006 is cross-sectional postmortem human data; no longitudinal quantification exists. The ratio likely varies by brain region and cell type (neuronal vs astrocytic T1). needs-replication
Human trial absence — No clinical trial has specifically targeted TrkB signaling for cognitive aging in healthy humans. 7,8-DHF is the most advanced probe but has not entered Phase 1 for aging. needs-human-replication
Arm-specific contributions to aging pathology — Which of the three effector arms is the primary bottleneck in aged brain (MAPK-CREB vs PI3K-AKT vs PLC-γ-CaMKII) is not established in humans. no-mechanism
BDNF vs TrkB.FL availability — In aged brain, BDNF ligand levels also decline; distinguishing a receptor-level (TrkB.FL:T1 ratio) from ligand-level (reduced BDNF secretion) bottleneck is methodologically difficult in postmortem samples. contradictory-evidence
WikiPathways ID — A dedicated WikiPathways entry for TrkB-specific signaling in humans was not confirmed at time of seeding. needs-canonical-id

Footnotes

doi:10.1098/rstb.2006.1894 · Reichardt LF · Phil Trans R Soc B 2006 · review · n=N/A · model: review of vertebrate neurotrophins · 2,137 citations · verified against local PDF (PMC1664664) ↩ ↩² ↩³
doi:10.1016/j.modgep.2006.03.009 · Webster MJ, Herman MM, Kleinman JE, Shannon Weickert C · Gene Expression Patterns 2006 · observational · n=postmortem human tissue series (hippocampus + temporal cortex) · model: human lifespan postmortem · 215 citations · not_oa (unverified locally) no-fulltext-access — TrkB.FL:T1 ratio aging shift, specific n, and age-range are unverified against full text; TrkB TK+ mRNA declines with age; TrkB TK- (T1) more stable across lifespan in temporal cortex ↩ ↩²
doi:10.1038/nrn2738 · Minichiello L · Nat Rev Neurosci 2009 · review · n=N/A · model: mouse knock-in genetics + review · 1,020 citations · not_oa (closed access; unverified locally) no-fulltext-access — Y515F/Y816F knock-in phenotypes and arm-specific LTP/memory claims derived from this source could not be verified against full text ↩ ↩² ↩³
doi:10.1111/j.1471-4159.2012.07882.x · Zeng Y, Lv F, Li L, Yu H, Dong M, Fu Q · J Neurochem 2012 · in-vivo · n=aged rats · model: aged Wistar rat · rescues spatial memory + synaptic plasticity with 7,8-DHF in cognitively impaired aged rats · not_oa (unverified locally) ↩ ↩²
doi:10.1073/pnas.0913572107 · Jang SW, Liu X, Yepes M, Shepherd KR, Miller GW, Liu Y, Wilson WD, Xiao G, Blanchi B, Sun YE, Ye K · PNAS 2010 · in-vivo + in-vitro · n=4–12 mice/group · model: mouse only (TrkB F616A knockin + C57BL/6; no aging arm) · 661 citations · verified against local PDF (PMC2823863) — identifies 7,8-DHF as selective TrkB agonist (activates TrkB but not TrkA or TrkC); BBB-penetrant i.p. 5 mg/kg; binds TrkB ECD CC-2 domain; Kd ≈ 320 nM; neuroprotective in KA, MCAO stroke, and MPTP-PD models in mice ↩
doi:10.1016/j.expneurol.2021.113652 · Fletcher JL et al. · Exp Neurol 2021 · in-vivo · n=mouse TBI model · model: Mus musculus · 56 citations · not_oa (closed access) — LM22A-4 neuroprotective in pediatric TBI; aging efficacy not directly tested ↩
doi:10.3390/cells10112834 · Dahlström M et al. · Cells 2021 · in-vivo · n=18-month mice · model: aged Mus musculus · ACD855/ACD856 PAMs restore cognition; single study; needs-replication ↩

🧬 Aging Wiki

Explorer

trkb-pathway